DM21

Overview

DM21 is a next-generation linker-payload that combines a maytansinoid microtubule-disrupting payload with a stable tripeptide linker. DM21 is conjugated with a humanized antibody against ADAM9 to obtain IMGC936.

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Antibody-Drug Conjugate/ADC Related | Products > Signaling Pathways > Cytoskeleton | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > Drug-Linker Conjugates for ADC | Products > Signaling Pathways > Microtubule/Tubulin

Product Information

• Catalog No.: HY-139441
• CAS No.: 2243689-80-5
• Molecular Formula: C58H83ClN8O16S
• Molecular Weight: 1215.84
• Purity: 99.34%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 0.83 mg/mL (0.68 mM); Clear solution
• Availability: In-stock

Source

Original product source